{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/prescribing-information/oral-corticosteroids/","result":{"pageContext":{"chapter":{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids","depth":2,"htmlHeader":"<!-- begin field f30b2bcf-efab-4680-9f52-80992eb93113 --><h2>Oral corticosteroids</h2><!-- end field f30b2bcf-efab-4680-9f52-80992eb93113 -->","summary":"","htmlStringContent":"<!-- begin item 68104a72-2a0e-4a34-bb71-b338fb406005 --><!-- end item 68104a72-2a0e-4a34-bb71-b338fb406005 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"05c59c48-e6ce-5ba4-a469-e3e4c9c76756","slug":"prescribing-issues","fullItemName":"Prescribing issues","depth":3,"htmlHeader":"<!-- begin field e3e85309-d642-4ff9-8608-9b3553d7e357 --><h3>What do I need to know about prescribing oral corticosteroids?</h3><!-- end field e3e85309-d642-4ff9-8608-9b3553d7e357 -->","summary":"","htmlStringContent":"<!-- begin item 816b2c7b-af00-4cbd-b818-e4a037535423 --><!-- begin field ef26a790-b5cb-4d6f-811d-e5f412ca2efd --><p><strong>Oral corticosteroids</strong> <strong>should be reserved for use in the treatment of severe flares, often while waiting for referral to secondary care where the condition can be fully assessed and other treatment options can be tried. </strong>See <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/severe-eczema/\">Scenario: Severe eczema</a> for more information.</p><ul><li><strong>Be aware that:</strong><ul><li>Frequent or prolonged use of systemic corticosteroids is associated with serious adverse effects, including growth retardation in children, diabetes mellitus, high blood pressure, and osteoporosis. However, these are unlikely to be a problem with a single course of prednisolone.</li><li>It is not necessary to taper the dose when stopping a one-week course of prednisolone.</li></ul></li><li><strong>For detailed prescribing information on oral corticosteroids, including contraindications and cautions, adverse effects, and drug interactions, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul><!-- end field ef26a790-b5cb-4d6f-811d-e5f412ca2efd --><!-- end item 816b2c7b-af00-4cbd-b818-e4a037535423 -->","subChapters":[]},{"id":"f5f79967-0a5f-54f3-b777-b6e3922a2eac","slug":"usage-instructions","fullItemName":"Usage instructions","depth":3,"htmlHeader":"<!-- begin field 9081a1ce-3d8d-4f66-a6ac-0a637364c0bc --><h3>What should I advise on how to use an oral corticosteroid?</h3><!-- end field 9081a1ce-3d8d-4f66-a6ac-0a637364c0bc -->","summary":"","htmlStringContent":"<!-- begin item 09f37cfb-4a9f-4b21-b514-5ebd9bb2fcda --><!-- begin field 6e8fed18-d363-4704-a7ac-47de09e4acbb --><ul><li><strong>Advise the person that:</strong><ul><li>Oral corticosteroids will have an immediate impact on the eczema and make them feel better, but they are for exceptional use and cannot be prescribed very often.</li><li>The use of topical corticosteroids is not necessary while oral prednisolone is being used (although emollients should still be used). However, they should use potent topical corticosteroids on the affected areas when the oral course has finished, as there is a risk of rebound eczema occurring after discontinuation of prednisolone.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Charman and Williams, 2003</a>]</p><!-- end field 6e8fed18-d363-4704-a7ac-47de09e4acbb --><!-- end item 09f37cfb-4a9f-4b21-b514-5ebd9bb2fcda -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}